Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -34.39% | 29.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -34.39% | 29.60% | |||
| Cost of Revenue | -25.63% | -4.74% | |||
| Gross Profit | -45.98% | 69.92% | |||
| SG&A Expenses | -2.20% | 1.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.21% | -3.10% | |||
| Operating Income | -22.70% | 33.71% | |||
| Income Before Tax | -44.10% | 28.88% | |||
| Income Tax Expenses | 14.94% | -0.34% | |||
| Earnings from Continuing Operations | -43.91% | 28.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.91% | 28.74% | |||
| EBIT | -22.70% | 33.71% | |||
| EBITDA | -25.36% | 35.61% | |||
| EPS Basic | -42.91% | 28.84% | |||
| Normalized Basic EPS | -20.26% | 29.52% | |||
| EPS Diluted | -42.91% | 28.84% | |||
| Normalized Diluted EPS | -20.26% | 29.52% | |||
| Average Basic Shares Outstanding | 0.70% | 0.13% | |||
| Average Diluted Shares Outstanding | 0.70% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||